CNN —An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, including those as young as 12, according to a new clinical trial. “The standard endpoint in studies of Hodgkin lymphoma is progression-free survival, because we think that best predicts the future,” he said. Hodgkin lymphoma can develop at any age, but it’s most common in early adulthood. ‘An immunotherapy revolution’The new study included nearly 1,000 people who were at least 12 years old and newly diagnosed with stage III or IV Hodgkin lymphoma that had previously been untreated. “However, insights in the field of cancer biology identified other potential approaches to cancer treatment in general and Hodgkin’s lymphoma in particular.

---

Persons: Hodgkin, Dr, Jonathan Friedberg, ”, ” Friedberg, it’s, Friedberg, Bristol, “, we’ve, Ann LaCasce, Dana, Farber, Brigham, Sanjay Gupta, James Armitage, Dan Longo, ” Armitage, Longo Organizations: CNN, New England, of Medicine, “, Wilmot Cancer Institute, University of Rochester, American Cancer Society, Bristol, Myers Squibb, Food and Drug Administration, FDA, Bristol Myers, Brigham Fellowship, CNN Health, University of Nebraska Medical Center, Brigham, Women’s Locations: United States, Canada, U.S